1 active not recruiting. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Active not recruiting 1 |
Follow repotrectinib: new trials by email Literature Review of repotrectinib trials Research Report on repotrectinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3) Repotrectinib, Crizotinib - Carcinoma, Non-Small-Cell Lung | Phase 3 | Active not recruiting | Bristol-Myers Squibb | 190 | 2023-12-21 | 2026-09-22 |
Carcinoma, Non-Small-Cell Lung (1)
Argentina (1) · Austria (1) · Brazil (1) · Canada (1) · Chile (1) · China (1) · France (1) · Germany (1) · Greece (1) · Hungary (1) · India (1) · Italy (1) · Japan (1) · Netherlands (1) · Poland (1)